Clinical trials located in

London

London city is located in United Kingdom. Currently, 20 clinical trials are being conducted in this city.

London, the capital of the United Kingdom, stands on the River Thames. Rich in history, it’s a blend of ancient and modern. The city houses four UNESCO World Heritage Sites: the Tower of London, Kew Gardens, the site comprising the Palace of Westminster, Westminster Abbey, and St Margaret’s Church, and the historic settlement of Greenwich. London’s remarkable Big Ben is not the clock but the 13.5-ton bell inside the clock tower. The London Underground, known as the Tube, is the world’s oldest underground railway network.

  • CT-EU-00117699

    Clinical Study of NX-1607 for Advanced Cancers

    This here clinical trial is called “A Study of NX-1607 in Adults With Advanced Malignancies”. The main purpose is to test the safety and effectiveness of a new drug called NX-1607 in treating different types of advanced cancers. NX-1607 is taken by mouth and works by blocking a protein called Cbl-b.

    The trial has two parts. In the first part, called Phase 1a, different doses of NX-1607 alone or combined with the chemo drug paclitaxel will be tested to find the highest safe dose. This part includes patients with cancers like ovarian, stomach, head and neck, melanoma, lung, prostate, mesothelioma, breast, bladder, cervical, colorectal, and lymphoma cancers.

    In the second part, called Phase 1b, the selected dose(s) from Phase 1a will be given to separate groups of patients with those same cancer types. The main goal here is to see if NX-1607, alone or with paclitaxel, can shrink or control the tumors. Safety will also still be closely watched.

    So in a nutshell, this study aims to find the right dose of an experimental drug NX-1607 and test if it has promising anti-cancer effects in a variety of advanced cancers that have limited treatment options remaining. Patient safety is the top priority throughout the trial.

    United Kingdom
  • Study of Combination Therapy for Melanoma After Anti-PD-1 Treatment

    This clinical trial is comparing two different treatment approaches for advanced melanoma, which is a type of skin cancer that has spread to other parts of the body. If you have a specific gene mutation called BRAF and have previously received treatment with certain immunotherapy drugs like nivolumab or pembrolizumab, you may be eligible for this study.

    One treatment approach involves receiving three study medicines: pembrolizumab given through an IV every 3 weeks, along with encorafenib and binimetinib taken by mouth daily at home. The other approach involves receiving two study medicines: ipilimumab and nivolumab given through an IV every 3 weeks for the first 4 doses, followed by nivolumab alone every 4 weeks. Both treatment approaches will be given for around 2 years, but there is no time limit for the encorafenib and binimetinib treatment.

    The study team will closely monitor your condition during regular visits to the clinic to see how you are responding to the treatment. The main goal is to determine which treatment approach is more effective in shrinking or eliminating the melanoma tumors. Around 150 participants will be enrolled in this study and randomly assigned to one of the two treatment groups.

    CzechiaGermanyItalyPolandSlovakiaSpainUnited Kingdom
  • Study of a new anticancer vaccine (SCIB1) in combination with immunotherapeutic drugs in the treatment of malignant melanoma

    The aim of this clinical trial is to test whether a new cancer vaccine called SCIB1 can be safely used with two approved treatments for advanced melanoma – nivolumab (Opdivo) plus ipilimumab (Yervoy) or pembrolizumab (Keytruda). The study will also examine whether adding SCIB1 to these therapies can increase the chances of melanoma responding to treatment and the duration of that response.

    Currently, SCIB1 is still considered experimental, but has been previously administered to melanoma patients and was well tolerated. Scientists have even seen some signs that it may help stimulate the immune system to fight cancer. In this study, SCIB1 will be administered up to 10 times over 85 weeks by injection into the arm or leg using a special needle-free device. Before starting treatment, you will undergo several screening tests to make sure you are eligible to take part.

    United Kingdom
  • Tebentafusp for the treatment of recurrent melanoma

    The study aims to investigate a new treatment for patients with cutaneous melanoma or uveal melanoma after surgery. Researchers want to see if a new drug called tebentafusp can help these patients live longer.

    Tebentafusp is a new drug that has already been studied in patients with advanced melanoma of the skin and uvea. In this study, this medicine will be administered to patients whose disease has relapsed at the molecular level using a special blood test. Patients will receive tebentafusp for up to 6 months as an intravenous infusion once a week and will then be followed for 12 months to check whether the disease has returned.

    United Kingdom
  • Treatment with Bel-Sar for patients with uveal melanoma

    The aim of this clinical trial is to test a new drug called Belzupacap Sarotalocan, or Bel-sar for short, for people with uveal melanoma.

    The main aim of this study is to test whether bel-sar is safe and effective compared to a dummy treatment, which acts as a placebo. The Bel-sar treatment involves injecting the drug (microinjection) into the eye space and then activating it with a special laser.

    The most important thing researchers want to know is how long it takes for the tumor to start growing again after treatment with bel-sar compared with sham treatment. They will closely monitor participants for up to 52 weeks to see how the situation progresses.

    United Kingdom
  • Study of darovasertib in patients with uveal melanoma

    This is a study of a new drug called darovasertib (also known as IDE196 or LXS196) in patients with primary choroidal melanoma. Darovasertib is an oral, potent and selective protein kinase C inhibitor that will be used to treat uveal melanoma.

    The aim of this study is to see if darovasertib can help reduce the size of the tumor before local treatment, such as removal of the eyeball or radiation. Patients will receive darovasertib for a maximum of 6 months before local treatment, and then for a further 6 months after local treatment. Doctors will watch to see if the drug helps avoid having to remove the eyeball or reduce the dose of radiation needed to treat the tumor.

    It is important to monitor for any side effects and changes in laboratory tests while taking darovasertib. Doctors will closely monitor the patient’s health throughout the study, which may last up to 3 years.

    FranceGermanyItalyNetherlandsUnited Kingdom
  • Study of a New Drug for Moderate to Severe Rotator Cuff Tendinopathy

    This here clinical trial is aimin’ to see if a new medicine called secukinumab can help folks with moderate to severe rotator cuff tendinopathy, which is a painful condition affectin’ the shoulder. The study will compare secukinumab to a placebo, which is like a fake medicine with no real effects.

    Now, if you join this trial, you’ll be given either secukinumab or the placebo by injection under the skin every week or so for the first few months. The doctors won’t know which one you’re gettin’ until later. You’ll also need to keep takin’ any anti-inflammatory medicines and doin’ physical therapy exercises as you normally would.

    The main thing the researchers are lookin’ at is whether secukinumab can better improve your physical shoulder symptoms like pain, weakness, stiffness, and such compared to the placebo. They’ll be askin’ you to rate your symptoms at different points durin’ the 24-week study.

    It’s important to know that you can’t increase your anti-inflammatory medicine doses or get steroid injections durin’ the study, but you can take other pain meds like acetaminophen if needed. The study involves some medical tests too, like MRI scans and X-rays of your shoulder.

    So in a nutshell, this trial aims to find out if secukinumab works better than a placebo at relievin’ the symptoms of rotator cuff tendinopathy when combined with standard treatments like physical therapy and anti-inflammatory drugs. If you’re interested, you’d be closely monitored and get either the new medicine or a placebo for free as part of the study.

    BulgariaCzechiaDenmarkFrancePortugalSlovakiaUnited Kingdom
  • Study assessing the effectiveness of Tebentafusp administered alone and in combination with Pembrolizumab in the treatment of advanced melanoma

    The aim of this study is to test new treatments for people with advanced skin melanoma that does not respond well to other therapies. The main focus was on a new experimental drug called tebentafusp, which is a special type of protein that helps the body’s immune system recognize and attack cancer cells.

    The study divided patients into three different groups. One group will receive tebentafusp alone. Another group will receive tebentafusp in combination with another immunotherapy drug called pembrolizumab. The third group will receive the treatment that the doctor thinks is best for the patient – this could be another experimental drug, standard therapy, or simply supportive care.

    Scientists are primarily focusing on the effectiveness of these treatments in shrinking tumors and extending patient survival. They will also monitor closely for any side effects to make sure the treatment is safe. The study is expected to last about two years and will include frequent check-ins to monitor patient responses.

    AustriaBelgiumFranceGermanyItalyPolandSpainUnited Kingdom
  • NCT05091346

    This here clinical trial is aimin’ to test out a new combination of drugs for treatin’ some tough cancers. The main drugs bein’ studied are E7386, a newfangled tablet, and pembrolizumab, which is given through an IV drip. For folks with liver cancer, they might also get lenvatinib capsules added to the mix.

    The first part of the trial is focused on findin’ the right doses of E7386 to use with pembrolizumab, makin’ sure the combination is safe and tolerable for patients. The doc’s will be keepin’ a close eye on any serious side effects durin’ this phase.

    If the doses look good, the second part will test how well this drug combo actually works against melanoma (skin cancer), colorectal cancer (cancer of the colon or rectum), and hepatocellular carcinoma (liver cancer). The main thing they’ll be measurin’ is the objective response rate, which means how many folks see their tumors shrinkin’ or disappearin’ altogether with this treatment.

    So in a nutshell, this trial is aimin’ to find a new, effective way to fight some of the toughest cancers out there usin’ a novel combination of medicines. If you’re interested in joinin’, be sure to ask your doctor about all the risks and benefits involved.

    SpainUnited Kingdom
  • Study of ATL001 T-Cell Therapy for Metastatic or Recurrent Melanoma

    This is a first-in-human study to test a new type of cancer treatment called ATL001 in patients with metastatic or recurrent melanoma (skin cancer that has spread or come back). ATL001 is made from your own immune cells that have been trained to recognize and attack your cancer cells. The study has two parts:

    First, some of your tumor tissue will be collected to manufacture the ATL001 treatment specifically for you. Then, you will receive chemotherapy to temporarily weaken your immune system before getting an infusion of the ATL001 cells. This allows the ATL001 cells to more easily find and fight your cancer.

    The main goal is to evaluate the safety of ATL001 and any side effects you may experience. The study will also look at whether ATL001 can help shrink or control your melanoma. You will be closely monitored for 24 months after receiving ATL001, and then followed for a minimum of 5 years to watch for any long-term effects.

    This is an open-label study, which means both you and your doctor will know you are receiving the ATL001 treatment. The study will take place at multiple medical centers, and you may be asked to travel for some visits or procedures.

    SpainUnited Kingdom
  • Study of the drug combination mRNA-4157/V940 and Pembrolizumab in the treatment of melanoma

    The aim of this clinical trial is to test whether a new drug called mRNA-4157/V940 in combination with pembrolizumab can help prevent the recurrence of melanoma in people who have already had it. Currently, mRNA-4157/V940 is what is called “individualized neoantigen therapy,” which means it is a therapy created specifically for each patient based on their cancer cells. Doctors give this drug along with pembrolizumab, a drug that helps the immune system fight cancer cells.

    The main goal of this study is to determine whether taking V940 and pembrolizumab together is more effective in preventing melanoma recurrence than taking pembrolizumab alone. Researchers will closely monitor how long it takes for the cancer to return or spread. The study will last for approximately 74 months.

    BelgiumDenmarkFranceGermanyGreeceItalyPolandPortugalSpainSwedenUnited Kingdom
  • Comparing ruxolitinib, hydroxycarbamide, and Interferon as first-line treatments for high-risk Polycythemia Vera

    The study, known as MITHRIDATE, investigates the effectiveness of the drug Ruxolitinib compared to either Hydroxycarbamide or Interferon Alpha for patients with high-risk Polycythemia Vera, a type of blood disorder. This Phase III clinical trial aims to determine which treatment is more effective in managing the disease without leading to additional health complications.

    Patients in the trial are assigned to receive either Ruxolitinib or the best available therapy, chosen from Hydroxycarbamide or Interferon Alpha, as decided by the overseeing doctors. The course of the study involves regular monitoring and assessments to evaluate the impact of these treatments on the disease’s progression and patients’ overall health and quality of life. The study is conducted in a controlled environment to ensure reliable results.

    United Kingdom
  • A study of sapablursen for patients with Polycythemia Vera requiring frequent blood removal

    This study evaluates the drug sapablursen (also known as ISIS 702843 or IONIS-TMPRSS6-LRx) in patients with polycythemia vera, a condition where the body makes too many red blood cells. The main purpose is to see if sapablursen can reduce the need for phlebotomy—a process of drawing blood to lower blood cell count—and improve patients’ quality of life. The study has four phases: screening, initial treatment, extended treatment, and post-treatment, lasting a total of about 96 weeks. Participants will receive sapablursen through subcutaneous injections. There is no placebo involved in this study.

    HungaryPolandUnited Kingdom
  • Study Comparing Asciminib and Nilotinib for Newly Diagnosed Chronic Myeloid Leukemia

    This study examines the effects and tolerance of two drugs, asciminib and nilotinib, for treating a specific type of leukemia called Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in its chronic phase. The participants are adults who have been newly diagnosed and have not received previous treatment for this condition. They will be randomly assigned to receive either asciminib or nilotinib. The study aims to see which drug is better tolerated and how effective they are. Throughout the study, participants will be monitored for any side effects and the progress of their treatment until they either experience significant side effects, the disease progresses, or they decide to stop the treatment. Follow-up checks will also be conducted after the treatment ends.

    BulgariaCzechiaFranceGermanyGreeceHungaryItalyNetherlandsRomaniaSlovakiaUnited Kingdom
  • A study comparing upadacitinib versus adalimumab in the treatment of rheumatoid arthritis

    This clinical trial is studying a new medication called upadacitinib for treating moderate to severe rheumatoid arthritis. Rheumatoid arthritis is a chronic condition that causes pain, stiffness, swelling, and loss of joint function. The study will compare upadacitinib, which is taken as an oral tablet once daily, to adalimumab (brand name Humira), which is an injection given under the skin every other week.

    The main goal is to see how effective upadacitinib is at reducing disease activity compared to adalimumab. The study will measure the percentage of participants who achieve a certain level of low disease activity based on a score called the DAS28-CRP, which looks at tender and swollen joints, overall disease activity, and inflammation levels.

    This is a double-blind study, meaning neither the participants nor the study doctors will know which treatment each participant is receiving. Participants will attend regular visits at a hospital or clinic for medical assessments, checking for side effects, and completing questionnaires. There may be a higher treatment burden compared to standard care. The study is designed to assess the safety and effectiveness of upadacitinib compared to adalimumab in treating moderate to severe rheumatoid arthritis.

    BelgiumBulgariaFranceGermanyGreeceHungaryItalyPortugalRomaniaSpainUnited Kingdom
  • Exploring a new vaccine regimen with Ipilimumab for myeloproliferative neoplasms

    This clinical trial is focused on evaluating the safety of a new treatment regimen for myeloproliferative neoplasms (MPNs), a type of blood disorder. The treatment involves **VAC85135**, a neoantigen vaccine, which will be given alongside **Ipilimumab**, a medication administered through an IV infusion. The main goal of this study is to understand how safe this combination is for patients with MPNs.

    This study is in its Phase 1, which means it’s the first time this treatment is being tested in people, with the main focus on safety. The trial will start by assessing the participants from the first day of receiving the treatment and will continue to monitor them for up to 79 weeks to capture any potential side effects that may occur.

    United Kingdom
  • To evaluate the safety and effects of GS-0272 in patients with rheumatoid arthritis or lupus

    A clinical trial is being introduced focusing on a new drug called GS-0272, intended for people with rheumatoid arthritis (RA) or systemic lupus erythematosus (SLE). The goal of this study is to gather more information about GS-0272, especially regarding its safety and good tolerability when administered in multiple doses.

    The Phase 1b study is designed to evaluate the safety, tolerability, pharmacokinetics, immunogenicity and pharmacodynamics of GS-0272 in adult participants with rheumatoid arthritis or systemic lupus erythematosus. The study will be conducted at multiple sites, and participants will be randomly assigned to receive the study drug GS-0272 or a placebo administered subcutaneously.

    The main goals of this study are to understand how safe GS-0272 is and how participants’ bodies respond to it after receiving multiple doses. Adverse events or serious adverse events will be closely monitored, as will any changes in laboratory test results that may indicate that the medicine is not well tolerated. Additionally, the study will examine how GS-0272 travels and is processed by the body, which is known as pharmacokinetics.

    This study is an important step in determining whether GS-0272 may be a beneficial treatment option for people with RA or SLE. The safety and well-being of participants are the highest priority and a commitment has been made to provide all necessary information and support throughout the study.

    GeorgiaMoldovaUnited Kingdom

See more clinical trials in other cities in United Kingdom:

.